Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multi-disciplinary approach

The Nephrotic Syndrome Study Network (NEPTUNE) is a North American multi-center collaborative consortium established to develop a translational research infrastructure for Nephrotic Syndrome. This includes a longitudinal observational cohort study, a pilot and ancillary studies program, a training program, and a patient contact registry. NEPTUNE will enroll 450 adults and children with minimal change disease, focal segmental glomerulosclerosis and membranous nephropathy for detailed clinical, histopathologic, and molecular phenotyping at the time of clinically-indicated renal biopsy. Initial visits will include an extensive clinical history, physical examination, collection of urine, blood and renal tissue samples, and assessments of quality of life and patient-reported outcomes. Follow-up history, physical measures, urine and blood samples, and questionnaires will be obtained every 4 months in the first year and bi-annually, thereafter. Molecular profiles and gene expression data will be linked to phenotypic, genetic, and digitalized histologic data for comprehensive analyses using systems biology approaches. Analytical strategies were designed to transform descriptive information to mechanistic disease classification for Nephrotic Syndrome and to identify clinical, histological, and genomic disease predictors. Thus, understanding the complexity of the disease pathogenesis will guide further investigation for targeted therapeutic strategies.

[1]  Jian Huang,et al.  Regularized binormal ROC method in disease classification using microarray data , 2005, BMC Bioinformatics.

[2]  H. Debiec,et al.  Frontiers in Research Review: Chronic Kidney Disease Advances in membranous nephropathy: Success stories of a long journey , 2011 .

[3]  S. Dudoit,et al.  Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data , 2002 .

[4]  D. Gipson,et al.  Management of Childhood Onset Nephrotic Syndrome , 2009, Pediatrics.

[5]  D. Cattran,et al.  The natural history of the non-nephrotic membranous nephropathy patient. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[6]  P. Diggle Analysis of Longitudinal Data , 1995 .

[7]  C. Cohen,et al.  Integrative biology of renal disease: toward a holistic understanding of the kidney's function and failure. , 2010, Seminars in nephrology.

[8]  R. Lazarus,et al.  A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. , 2010, Kidney international.

[9]  O. Gribouval,et al.  NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. , 2004, Kidney international.

[10]  Xiao-Hua Zhou,et al.  Statistical Methods in Diagnostic Medicine , 2002 .

[11]  G. Remuzzi,et al.  Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  C. Ponticelli,et al.  Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. , 1997, Kidney international.

[13]  L. Kiemeney,et al.  Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. , 2011, The New England journal of medicine.

[14]  Kirsten L. Johansen,et al.  US Renal Data System 2011 Annual Data Report , 2012 .

[15]  P. Perco,et al.  Integrative analysis of -omics data and histologic scoring in renal disease and transplantation: renal histogenomics. , 2010, Seminars in nephrology.

[16]  E. Jones,et al.  Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  E. Bertini,et al.  COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. , 2007, Journal of the American Society of Nephrology : JASN.

[18]  W. Ju,et al.  Understanding kidney disease: toward the integration of regulatory networks across species. , 2010, Seminars in nephrology.

[19]  V. D’Agati,et al.  Clinical trial of focal segmental glomerulosclerosis in children and young adults. , 2011, Kidney international.

[20]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[21]  Joni K. Evans,et al.  Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. , 1999, Journal of the American Society of Nephrology : JASN.

[22]  Peter Nürnberg,et al.  Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible , 2006, Nature Genetics.

[23]  R. Ferrell,et al.  Familial nephrotic syndrome: clinical spectrum and linkage to chromosome 19q13. , 2000, Kidney international.

[24]  C. Jones,et al.  Clinical spectrum of Denys-Drash and Frasier syndrome , 2001, Pediatric Nephrology.

[25]  R. Colvin,et al.  Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease. , 2012, Archives of pathology & laboratory medicine.

[26]  H. Schnaper,et al.  A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[27]  M. Pericak-Vance,et al.  Clinical and genetic heterogeneity in familial focal segmental glomerulosclerosis. International Collaborative Group for the Study of Familial Focal Segmental Glomerulosclerosis. , 1999, Kidney international.

[28]  S. Rosset,et al.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene , 2010, Human Genetics.

[29]  M. Haas,et al.  Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  Y. Pei,et al.  Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. , 1992, Kidney international.

[31]  R. Simon,et al.  Sample size planning for developing classifiers using high-dimensional DNA microarray data. , 2007, Biostatistics.

[32]  L. Barisoni,et al.  Current views on collapsing glomerulopathy. , 2008, Journal of the American Society of Nephrology : JASN.

[33]  Colleen J. Thomas,et al.  Do prostanoids or nitric oxide mediate sensitization of the von Bezold–Jarisch reflex by B‐type natriuretic peptide? , 2011, Clinical and experimental pharmacology & physiology.

[34]  Ravi Iyengar,et al.  Systems biology of kidney diseases. , 2012, Kidney international.

[35]  D. Vlahov,et al.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008, Nature Genetics.

[36]  T. Srivastava,et al.  High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood , 1999, Pediatric Nephrology.

[37]  U. Sauer,et al.  Getting Closer to the Whole Picture , 2007, Science.

[38]  B. Maček,et al.  Toward quantitative proteomics of organ substructures: implications for renal physiology. , 2010, Seminars in nephrology.

[39]  Benjamin J. Keller,et al.  A systems view of genetics in chronic kidney disease. , 2012, Kidney international.

[40]  J. Cameron Membranous nephropathy and its treatment. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  Sandrine Florquin,et al.  The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. , 2009, Kidney international.